{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:23:30Z","timestamp":1788895410287,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007913","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["147; KCL-BCN-Q3"],"award-info":[{"award-number":["147; KCL-BCN-Q3"]}],"id":[{"id":"10.13039\/501100007913","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC","award":["MR\/X012476\/1"],"award-info":[{"award-number":["MR\/X012476\/1"]}]},{"name":"CRUK City of London Centre","award":["CANCTA-2022\/100001"],"award-info":[{"award-number":["CANCTA-2022\/100001"]}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2021\/1407 JS, 2024\/3591 JS"],"award-info":[{"award-number":["CAN 2021\/1407 JS, 2024\/3591 JS"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","award":["FBKS-2020-5 JS and FBKS-2024-14 JS"],"award-info":[{"award-number":["FBKS-2020-5 JS and FBKS-2024-14 JS"]}],"id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-01800, 2025-02643"],"award-info":[{"award-number":["2021-01800, 2025-02643"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BCF-V\u00d6S Foundation"},{"name":"the National Society of Breast Cancer Associations in Sweden"},{"name":"Swedish governmental funding","award":["2022\/0021"],"award-info":[{"award-number":["2022\/0021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DNA methylation deregulation is an essential feature of tumor biology, influencing cancer formation and pathogenesis. Analyses of DNA methylation in bulk cancer specimens are challenging due to the high data dimensionality, noise, and mixture of different cell types. Here, we characterized methylation dynamics in cancer by investigating the variance structure of bulk tumor DNA methylation data through the identification of groups of highly correlated CpGs, termed CpG cassettes. Using triple-negative breast cancer as a model system, our approach identified co-occurring methylation patterns linked to different intrinsic tumor processes and pathways, gene inactivation, and composition of the tumor immune microenvironment. Our framework also demonstrated the presence of high-variance DNA methylation, seemingly not linked to tumor biology, that could be excluded using chromatin accessibility filtering. Together, this work outlines a comprehensive approach to analyze bulk tumor DNA methylation data, combining tumor purity adjustment, functional CpG filtering, stratification by CpG contexts, and identification of highly correlated CpG modules to enhance tumor-intrinsic DNA methylation patterns and our understanding of processes shaping epigenetic tumor evolution.<\/jats:p>","DOI":"10.1038\/s41523-026-01030-y","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:24:48Z","timestamp":1786519488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genome-wide DNA methylation profiling of triple-negative breast cancer uncovers epigenetic biomarkers of tumor identity and the immune microenvironment"],"prefix":"10.1038","volume":"12","author":[{"given":"I\u00f1aki","family":"Sasiain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F.","family":"Nacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vallon-Christersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Aine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Staaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1030_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","volume":"945","author":"R Lakshminarasimhan","year":"2016","unstructured":"Lakshminarasimhan, R. & Liang, G. The role of DNA methylation in cancer. Adv. Exp. Med. Biol. 945, 151\u2013172 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1030_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik, D. et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat. Commun. 11, 3747 (2020).","journal-title":"Nat. Commun."},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","volume":"112","author":"RD Kalachand","year":"2020","unstructured":"Kalachand, R. D. et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. 112, 1190\u20131203 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"1030_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46422-5","volume":"15","author":"C Li","year":"2024","unstructured":"Li, C. et al. Mi-2beta promotes immune evasion in melanoma by activating EZH2 methylation. Nat. Commun. 15, 2163 (2024).","journal-title":"Nat. Commun."},{"key":"1030_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung, H. et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat. Commun. 10, 4278 (2019).","journal-title":"Nat. Commun."},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"e0130409","DOI":"10.1371\/journal.pone.0130409","volume":"10","author":"K Shigeyasu","year":"2015","unstructured":"Shigeyasu, K. et al. Clinical significance of MLH1 methylation and CpG island methylator phenotype as prognostic markers in patients with gastric cancer. PLoS ONE 10, e0130409 (2015).","journal-title":"PLoS ONE"},{"key":"1030_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0145-3","volume":"6","author":"MJ Fackler","year":"2020","unstructured":"Fackler, M. J. et al. DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. npj Breast Cancer 6, 3 (2020).","journal-title":"npj Breast Cancer"},{"key":"1030_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0795-x","volume":"11","author":"I Rauluseviciute","year":"2019","unstructured":"Rauluseviciute, I., Drablos, F. & Rye, M. B. DNA methylation data by sequencing: experimental approaches and recommendations for tools and pipelines for data analysis. Clin. Epigenetics 11, 193 (2019).","journal-title":"Clin. Epigenetics"},{"key":"1030_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r31","volume":"15","author":"AE Jaffe","year":"2014","unstructured":"Jaffe, A. E. & Irizarry, R. A. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 15, R31 (2014).","journal-title":"Genome Biol."},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fgene.2019.00349","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Prognostic and predictive value of three DNA methylation signatures in lung adenocarcinoma. Front. Genet. 10, 349 (2019).","journal-title":"Front. Genet."},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1245\/s10434-019-07565-8","volume":"26","author":"ML DiNome","year":"2019","unstructured":"DiNome, M. L. et al. Clinicopathological features of triple-negative breast cancer epigenetic subtypes. Ann. Surg. Oncol. 26, 3344\u20133353 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"1030_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100306","volume":"36","author":"LH Lin","year":"2023","unstructured":"Lin, L. H. et al. DNA methylation identifies epigenetic subtypes of triple-negative breast cancers with distinct clinicopathologic and molecular features. Mod. Pathol. 36, 100306 (2023).","journal-title":"Mod. Pathol."},{"key":"1030_CR14","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.1073\/pnas.0914005107","volume":"107","author":"R Bourgon","year":"2010","unstructured":"Bourgon, R., Gentleman, R. & Huber, W. Independent filtering increases detection power for high-throughput experiments. Proc. Natl. Acad. Sci. USA 107, 9546\u20139551 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1030_CR15","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1200\/JCO.2012.48.5516","volume":"31","author":"J Sandoval","year":"2013","unstructured":"Sandoval, J. et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 31, 4140\u20134147 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1030_CR16","doi-asserted-by":"publisher","first-page":"e0265557","DOI":"10.1371\/journal.pone.0265557","volume":"17","author":"J Staaf","year":"2022","unstructured":"Staaf, J. & Aine, M. Tumor purity adjusted beta values improve biological interpretability of high-dimensional DNA methylation data. PLoS ONE 17, e0265557 (2022).","journal-title":"PLoS ONE"},{"key":"1030_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqae146","volume":"6","author":"I Sasiain","year":"2024","unstructured":"Sasiain, I., Nacer, D. F., Aine, M., Veerla, S. & Staaf, J. Tumor purity estimated from bulk DNA methylation can be used for adjusting beta values of individual samples to better reflect tumor biology. NAR Genom. Bioinform. 6, lqae146 (2024).","journal-title":"NAR Genom. Bioinform."},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2018.02.003","volume":"5","author":"Y Qin","year":"2018","unstructured":"Qin, Y., Feng, H., Chen, M., Wu, H. & Zheng, X. InfiniumPurify: An R package for estimating and accounting for tumor purity in cancer methylation research. Genes Dis. 5, 43\u201345 (2018).","journal-title":"Genes Dis."},{"key":"1030_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-3-r21","volume":"14","author":"D Aran","year":"2013","unstructured":"Aran, D., Sabato, S. & Hellman, A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 14, R21 (2013).","journal-title":"Genome Biol."},{"key":"1030_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2013.06.018","volume":"154","author":"D Aran","year":"2013","unstructured":"Aran, D. & Hellman, A. DNA methylation of transcriptional enhancers and cancer predisposition. Cell 154, 11\u201313 (2013).","journal-title":"Cell"},{"key":"1030_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58158-x","volume":"16","author":"M Aine","year":"2025","unstructured":"Aine, M. et al. The DNA methylation landscape of primary triple-negative breast cancer. Nat. Commun. 16, 3041 (2025).","journal-title":"Nat. Commun."},{"key":"1030_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1030_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. npj Breast Cancer 8, 95 (2022).","journal-title":"npj Breast Cancer"},{"key":"1030_CR24","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1030_CR25","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Investig."},{"key":"1030_CR26","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11, e0157368 (2016).","journal-title":"PLoS ONE"},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","volume":"25","author":"J Staaf","year":"2019","unstructured":"Staaf, J. et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat. Med. 25, 1526\u20131533 (2019).","journal-title":"Nat. Med."},{"key":"1030_CR28","first-page":"5277","volume":"9","author":"R Huang","year":"2015","unstructured":"Huang, R., Ding, P. & Yang, F. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Drug Des. Dev. Ther. 9, 5277\u20135285 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"1030_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72306-1","volume":"14","author":"S Roostee","year":"2024","unstructured":"Roostee, S. et al. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells. Sci. Rep. 14, 21417 (2024).","journal-title":"Sci. Rep."},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","volume":"3","author":"T Karn","year":"2017","unstructured":"Karn, T. et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 3, 1707\u20131711 (2017).","journal-title":"JAMA Oncol."},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.18632\/oncotarget.497","volume":"3","author":"D Jjingo","year":"2012","unstructured":"Jjingo, D., Conley, A. B., Yi, S. V., Lunyak, V. V. & Jordan, I. K. On the presence and role of human gene-body DNA methylation. Oncotarget 3, 462\u2013474 (2012).","journal-title":"Oncotarget"},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"e1001057","DOI":"10.1371\/journal.pcbi.1001057","volume":"7","author":"P Langfelder","year":"2011","unstructured":"Langfelder, P., Luo, R., Oldham, M. C. & Horvath, S. Is my network module preserved and reproducible? PLoS Comput. Biol. 7, e1001057 (2011).","journal-title":"PLoS Comput. Biol."},{"key":"1030_CR33","doi-asserted-by":"publisher","unstructured":"Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, https:\/\/doi.org\/10.1126\/science.aav1898 (2018).","DOI":"10.1126\/science.aav1898"},{"key":"1030_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi, S. et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann. Oncol. 32, 1236\u20131244 (2021).","journal-title":"Ann. Oncol."},{"key":"1030_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3236","volume":"14","author":"E Fredlund","year":"2012","unstructured":"Fredlund, E. et al. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 14, R113 (2012).","journal-title":"Breast Cancer Res."},{"key":"1030_CR36","doi-asserted-by":"publisher","first-page":"e0204513","DOI":"10.1371\/journal.pone.0204513","volume":"13","author":"K Harano","year":"2018","unstructured":"Harano, K. et al. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE 13, e0204513 (2018).","journal-title":"PLoS ONE"},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","volume":"216","author":"K Tretina","year":"2019","unstructured":"Tretina, K., Park, E. S., Maminska, A. & MacMicking, J. D. Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease. J. Exp. Med. 216, 482\u2013500 (2019).","journal-title":"J. Exp. Med."},{"key":"1030_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00154-7","volume":"5","author":"JH Jang","year":"2021","unstructured":"Jang, J. H., Kim, D. H. & Surh, Y. J. Dynamic roles of inflammasomes in inflammatory tumor microenvironment. npj Precis. Oncol. 5, 18 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1030_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00432-024-05605-9","volume":"150","author":"W Zhou","year":"2024","unstructured":"Zhou, W., Yeerkenbieke, G., Zhang, Y., Zhou, M. & Li, J. Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. J. Cancer Res. Clin. Oncol. 150, 90 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1030_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00262-024-03786-3","volume":"73","author":"Y Tasiheng","year":"2024","unstructured":"Tasiheng, Y. et al. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Cancer Immunol. Immunother. 73, 208 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"1030_CR41","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/0008-5472.CAN-23-3298","volume":"84","author":"H Liao","year":"2024","unstructured":"Liao, H. et al. Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers. Cancer Res. 84, 1747\u20131763 (2024).","journal-title":"Cancer Res."},{"key":"1030_CR42","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.molcel.2025.05.001","volume":"85","author":"V Merold","year":"2025","unstructured":"Merold, V. et al. Structural basis for OAS2 regulation and its antiviral function. Mol. Cell 85, 2176\u20132193.e2113 (2025).","journal-title":"Mol. Cell"},{"key":"1030_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06889-y","volume":"15","author":"F Xie","year":"2024","unstructured":"Xie, F. et al. ZBP1 condensate formation synergizes Z-NAs recognition and signal transduction. Cell Death Dis. 15, 487 (2024).","journal-title":"Cell Death Dis."},{"key":"1030_CR44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","volume":"606","author":"T Zhang","year":"2022","unstructured":"Zhang, T. et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature 606, 594\u2013602 (2022).","journal-title":"Nature"},{"key":"1030_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23004-3","volume":"12","author":"JY Baik","year":"2021","unstructured":"Baik, J. Y. et al. ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer. Nat. Commun. 12, 2666 (2021).","journal-title":"Nat. Commun."},{"key":"1030_CR46","doi-asserted-by":"publisher","unstructured":"Peng, S. et al. Structure and function of an effector domain in antiviral factors and tumor suppressors SAMD9 and SAMD9L. Proc. Natl. Acad. Sci. USA 119, https:\/\/doi.org\/10.1073\/pnas.2116550119 (2022).","DOI":"10.1073\/pnas.2116550119"},{"key":"1030_CR47","doi-asserted-by":"publisher","unstructured":"Holland, M., Rutkowski, R. & C. Levin, T. Evolutionary dynamics of proinflammatory caspases in primates and rodents. Mol. Biol. Evol. 41, https:\/\/doi.org\/10.1093\/molbev\/msae220 (2024).","DOI":"10.1093\/molbev\/msae220"},{"key":"1030_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112265","volume":"42","author":"S Devi","year":"2023","unstructured":"Devi, S. et al. CARD-only proteins regulate in vivo inflammasome responses and ameliorate gout. Cell Rep. 42, 112265 (2023).","journal-title":"Cell Rep."},{"key":"1030_CR49","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.cell.2021.03.023","volume":"184","author":"E Gangoso","year":"2021","unstructured":"Gangoso, E. et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell 184, 2454\u20132470.e26 (2021).","journal-title":"Cell"},{"key":"1030_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0131-9","volume":"7","author":"LH Saal","year":"2015","unstructured":"Saal, L. H. et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 7, 20 (2015).","journal-title":"Genome Med."},{"key":"1030_CR51","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1002\/bjs.10741","volume":"105","author":"L Ryden","year":"2018","unstructured":"Ryden, L. et al. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br. J. Surg. 105, e158\u2013e168 (2018).","journal-title":"Br. J. Surg."},{"key":"1030_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00465-3","volume":"8","author":"J Staaf","year":"2022","unstructured":"Staaf, J. et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. npj Breast Cancer 8, 94 (2022).","journal-title":"npj Breast Cancer"},{"key":"1030_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01392-0","volume":"23","author":"M Aine","year":"2021","unstructured":"Aine, M. et al. Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Res. 23, 20 (2021).","journal-title":"Breast Cancer Res."},{"key":"1030_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-024-07561-x","volume":"210","author":"G Sigurjonsdottir","year":"2025","unstructured":"Sigurjonsdottir, G. et al. Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort. Breast Cancer Res. Treat. 210, 271\u2013284 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"1030_CR55","doi-asserted-by":"publisher","unstructured":"Fishilevich, S. et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database 2017, https:\/\/doi.org\/10.1093\/database\/bax028 (2017).","DOI":"10.1093\/database\/bax028"},{"key":"1030_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100736","volume":"38","author":"YJ Cha","year":"2025","unstructured":"Cha, Y. J. et al. Genomic characteristics related to histology-based immune features in breast cancer. Mod. Pathol. 38, 100736 (2025).","journal-title":"Mod. Pathol."},{"key":"1030_CR57","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-015-3401-8","volume":"151","author":"BY Hair","year":"2015","unstructured":"Hair, B. Y. et al. Body mass index associated with genome-wide methylation in breast tissue. Breast Cancer Res. Treat. 151, 453\u2013463 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"1030_CR58","doi-asserted-by":"publisher","first-page":"e2341651","DOI":"10.1001\/jamanetworkopen.2023.41651","volume":"6","author":"BD Jenkins","year":"2023","unstructured":"Jenkins, B. D. et al. Neighborhood deprivation and DNA methylation and expression of cancer genes in breast tumors. JAMA Netw. Open 6, e2341651 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1030_CR59","doi-asserted-by":"publisher","first-page":"e41361","DOI":"10.1371\/journal.pone.0041361","volume":"7","author":"LE Reinius","year":"2012","unstructured":"Reinius, L. E. et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS ONE 7, e41361 (2012).","journal-title":"PLoS ONE"},{"key":"1030_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41588-024-01688-9","volume":"56","author":"AD Reed","year":"2024","unstructured":"Reed, A. D. et al. A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast. Nat. Genet. 56, 652\u2013662 (2024).","journal-title":"Nat. Genet."},{"key":"1030_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113564","volume":"42","author":"B Jovanovic","year":"2023","unstructured":"Jovanovic, B. et al. Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Rep. 42, 113564 (2023).","journal-title":"Cell Rep."},{"key":"1030_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-022-01236-2","volume":"9","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Pal, B., Lindeman, G. J., Visvader, J. E. & Smyth, G. K. R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue. Sci. Data 9, 96 (2022).","journal-title":"Sci. Data"},{"key":"1030_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for Weighted Correlation Network Analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"key":"1030_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07155-4","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy, A. et al. Author Correction: Pan-cancer deconvolution of tumour composition using DNA methylation. Nat. Commun. 9, 4642 (2018).","journal-title":"Nat. Commun."},{"key":"1030_CR65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1030_CR66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/bioinformatics\/btv560","volume":"32","author":"B Phipson","year":"2016","unstructured":"Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing data from Illumina\u2019s HumanMethylation450 platform. Bioinformatics 32, 286\u2013288 (2016).","journal-title":"Bioinformatics"},{"key":"1030_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02388-x","volume":"22","author":"J Maksimovic","year":"2021","unstructured":"Maksimovic, J., Oshlack, A. & Phipson, B. Gene set enrichment analysis for genome-wide DNA methylation data. Genome Biol. 22, 173 (2021).","journal-title":"Genome Biol."},{"key":"1030_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1030_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa, M. B. & Rudnicki, W. R. Feature selection with the Boruta Package. J. Stat. Softw. 36, 1\u201313 (2010).","journal-title":"J. Stat. Softw."},{"key":"1030_CR70","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1030_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","volume":"19","author":"G Palla","year":"2022","unstructured":"Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. Nat. Methods 19, 171\u2013178 (2022).","journal-title":"Nat. Methods"},{"key":"1030_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"1030_CR73","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01030-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:43:08Z","timestamp":1786520588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01030-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-01030-y","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"105"}}